Seira Nishibe-Toyosato   Yosuke Ando   Yasuhiro Goto   Takahiro Hayashi   Kaori Ito   Hidezo Matsuda   Naho Tsujii   Masahiro Tsuge   Kenji Kawada   Kazuyoshi Imaizumi   Shigeki Yamada   
Biological & pharmaceutical bulletin 44(9) 1280-1285 2021年9月
Erlotinib is used to treat advanced non-small-cell lung cancer (NSCLC), the common serious adverse events are skin disorders. The dose intensity of erlotinib should be maintained as much as possible by an appropriate control of adverse events in o...